93 completed, 11 terminated, 7 unknown, 6 active not recruiting. 122 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 122 | Completed 93, Terminated 11, Unknown 7, Active not recruiting 6, Withdrawn 3, Not yet recruiting 1, Recruiting 1 |
Follow Amgen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma Evolocumab, Routine Lipid Management, Autoinjector - Coronary Artery Disease, Hypercholesterolemia | Phase 4 | Not yet recruiting | Amgen | 308 | 2027-01-31 | 2026-09-21 |
| A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China Prolia® - Glucocorticoid-induced Osteoporosis | Phase 4 | Active not recruiting | Amgen | 102 | 2025-05-24 | 2026-05-27 |
| Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China Prolia - Osteoporosis | Phase 4 | Active not recruiting | Amgen | 102 | 2024-08-06 | 2026-02-12 |
| Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) Blood tests, Inebilizumab - Neuromyelitis Optica Spectrum Disorder | Phase 4 | Active not recruiting | Amgen | 32 | 2024-04-02 | 2025-11-21 |
| A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout Pegloticase, Methotrexate - Gout | Phase 4 | Completed | Amgen | 306 | 2024-03-18 | 2026-09-17 |
| A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis Avacopan, Placebo, Standard of Care - Antineutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 4 | Recruiting | Amgen | 300 | 2024-02-07 | 2026-11-13 |
| Rivaroxaban Sotorasib Interaction Study Rivaroxaban 20mg, Sotorasib 960mg - Drug Drug Interaction Study | Phase 4 | Completed | Radboud University Medical Center | 21 | 2023-11-09 | 2024-04-30 |
| A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture. Romosozumab - Postmenopausal Osteoporosis | Phase 4 | Completed | Amgen | 100 | 2023-10-30 | 2026-10-21 |
| Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone XGEVA® - Giant Cell Tumor of Bone | Phase 4 | Active not recruiting | Amgen | 36 | 2023-08-17 | 2025-10-01 |
| EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction Evolocumab, Routine Lipid Management - Cardiovascular Disease, Myocardial Infarction | Phase 4 | Active not recruiting | Amgen | 6019 | 2022-10-26 | 2026-11-09 |
| Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI Evolocumab 140 MG/ML, Standard of care (SOC) - STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI | Phase 4 | Active not recruiting | Assistance Publique - Hôpitaux de Paris | 2166 | 2021-09-29 | 2026-04-13 |
| TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study Teprotumumab, Placebo - Thyroid Eye Disease | Phase 4 | Completed | Amgen | 313 | 2021-09-16 | 2026-08-21 |
| A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease TEPEZZA, Placebo - Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease | Phase 4 | Completed | Amgen | 62 | 2021-09-02 | 2024-07-01 |
| Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) Blinatumomab, Current Wearable Heatlth Monitoring System (CWHMS) - B-precursor Acute Lymphoblastic Leukemia | Phase 4 | Terminated | Amgen | 10 | 2021-08-26 | 2025-05-18 |
| Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging Etanercept, OCT - Psoriasis, Psoriatic Arthritis | Phase 4 | Unknown | OptiSkin Medical | 10 | 2021-08-09 | 2022-01-06 |
| A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine Erenumab - Migraine | Phase 4 | Completed | Amgen | 240 | 2021-06-11 | 2024-09-19 |
| Reducing Intracranial atheroSclErosis With Repatha Repatha - Ischemic Stroke | Phase 4 | Terminated | University of California, Los Angeles | 10 | 2021-04-23 | 2023-03-15 |
| Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy Pegloticase, Methotrexate (MTX) - Uncontrolled Gout | Phase 4 | Completed | Amgen | 11 | 2021-03-08 | 2024-06-27 |
| Lipid Management in Renal Transplant Recipients Using Evolocumab. Evolocumab - Hyperlipidemias | Phase 4 | Completed | Brigham and Women's Hospital | 81 | 2021-02-17 | 2026-04-16 |
| Erenumab for Idiosyncratic Facial Pain Erenumab Prefilled Syringe, Placebo - Facial Pain, Rhinosinusitis | Phase 4 | Completed | David Jang, M.D. | 29 | 2021-02-10 | 2024-09-24 |
Showing 20 of 122. Sign in to see all of them.
Arthritis, Rheumatoid (15) · Anemia (13) · Psoriasis (13) · Renal Insufficiency, Chronic (12) · Hyperparathyroidism, Secondary (8) · Kidney Diseases (8) · Gout (6) · Migraine Disorders (6) · Osteoporosis (6) · Arthritis (5) · Kidney Failure, Chronic (5) · Arthritis, Psoriatic (4) · Heart Failure (4) · Hypercholesterolemia (4) · Neoplasms (4)
Etanercept (28) · evolocumab (13) · Darbepoetin alfa (12) · Methotrexate (10) · Cinacalcet (9) · Denosumab (7) · Pegloticase (7) · erenumab (6) · Ivabradine (4) · apremilast (4) · Standard of Care (3) · Vitamin D (3) · glycerol phenylbutyrate (3) · Epoetin Alfa (2) · Folic Acid (2)
United States (60) · Canada (18) · Spain (10) · Italy (9) · France (7) · Poland (7) · United Kingdom (7) · Denmark (6) · Germany (6) · Austria (5) · Czechia (5) · Belgium (4) · China (4) · Hungary (4) · India (4)
Leonardo Clavijo, MD, PhD (2) · Robert Bissonnette, MD (2) · Anil K Chandraker, MD (1) · Bente L Langdahl, MD PhD DMSc (1) · Boni E Elewski, MD (1) · Carol A. Wallace, MD (1) · Charlotte B Norager, M.D. (1) · David Jang, MD (1) · Dominick Angiolillo, MD, PhD (1) · Dr Lalit Lakhwani, MD (1) · Eugenia Raichlin, MD (1) · Hannu T Aro, MD, PhD (1) · Henry Ginsberg, MD (1)
PMID 18328118, PMID 42825996, PMID 16614237, PMID 17092858, PMID 17373192, PMID 17470434, PMID 17470691, PMID 17500381, PMID 17522247, PMID 17621407, PMID 17666472, PMID 17694552, PMID 17853307, PMID 18165618, PMID 18178780, PMID 18380206, PMID 18576334, PMID 18632499, PMID 19317607, PMID 19365139, PMID 19470620, PMID 20118030, PMID 20943783, PMID 21455550, PMID 21693239, PMID 21797805, PMID 22183975, PMID 22508468, PMID 22730343, PMID 22863242, PMID 24356474, PMID 24786928, PMID 24907147, PMID 25873267, PMID 26361879, PMID 26606398, PMID 27006728, PMID 27188329, PMID 27334320, PMID 27388672, PMID 27483410, PMID 28538380, PMID 28916119, PMID 29462231, PMID 29941047, PMID 30217721, PMID 31651370, PMID 31849542, PMID 32163613, PMID 32217365
2018 (5), 2015 (2), 2019 (2), 2016 (1), 2017 (1), R01AR049762 (1), R01DK032333 (1)